All In Biotech

Drug Trial Radar · NCT06961084

Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer

Comparison of I-124 PET/CT to I-123 Whole Body Imaging for the Diagnosis of Thyroid

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Dec 4, 2025

Primary completion

Apr 1, 2028

Study completion Apr 1, 2028

Sponsor

Lead sponsor
Thomas HopeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense
First posted
May 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.

Conditions

  • Thyroid Cancer

Interventions

  • Iodine-124Drug

    Given Orally

  • Positron Emission Tomography (PET)/Computerized tomography (CT)Procedure

    Combination of PET and CT imaging

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of agreement between I-124 PET and I-123/I-131 SPECT (participant)Time frame: 1 day
  2. Number of agreement between 1-124 PET and 1-123/1-131 SPECT (region)Time frame: 1 day

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.